8-K
Teladoc Health, Inc. (TDOC)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
___________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) March 30, 2026
___________________________________
Teladoc Health, Inc.
(Exact name of registrant as specified in its charter)
___________________________________
| Delaware<br><br>(State or other jurisdiction of<br><br>incorporation) | 001-37477<br><br>(Commission File Number) | 04-3705970<br><br>(I.R.S. Employer Identification No.) |
|---|---|---|
| 155 E 44th Street Suite 1700<br><br>New York, NY 10017 | ||
| (Address of principal executive offices and zip code) | ||
| (203) 635-2002 | ||
| (Registrant's telephone number, including area code) |
___________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||
|---|---|---|---|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | Securities registered pursuant to Section 12(b) of the Act: | |||
| --- | --- | --- | |||
| Title of each class | Trading Symbol | Name of each exchange on which registered | |||
| Common stock, par value $0.001 per share | TDOC | The New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective March 30, 2026, the Board of Directors (the “Board”) of Teladoc Health, Inc. (the “Company”) increased the number of directors on the Board to nine and appointed Susan R. Salka as a director of the Company. Ms. Salka was additionally appointed to each of the audit committee and the compensation committee of the Board. The Board has determined that Ms. Salka is an independent director within the meaning of the New York Stock Exchange listing standards and is an “audit committee financial expert” under Securities and Exchange Commission (the “SEC”) and New York Stock Exchange rules.
There are no arrangements or understandings between Ms. Salka and any other person pursuant to which she was selected as a director. There are no transactions involving the Company and Ms. Salka that the Company would be required to report pursuant to Item 404(a) of Regulation S-K.
Ms. Salka will have the same director indemnification arrangement as do the Company’s other directors appointed since October 2020, the form of agreement for which was filed with the SEC on March 1, 2021 as Exhibit 10.2 to the Company’s Annual Report on Form 10-K. Ms. Salka will be eligible to participate in the compensation arrangements and programs that are established for the Company’s non-employee directors, as in effect from time to time, which are described in the Company’s Proxy Statement on Schedule 14A filed with the SEC on April 8, 2025.
Item 7.01 Regulation FD.
On March 30, 2026, the Company issued a press release regarding the matter discussed in Item 5.02 of this Current Report. A copy of the press release is furnished herewith as Exhibit 99.1.
The information furnished under this Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description |
|---|---|
| 99.1 | Teladoc Health, Inc. press release, dated March 30, 2026. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 30, 2026
| Teladoc Health, Inc. | |
|---|---|
| By: | /s/ Adam C. Vandervoort |
| Name: | Adam C. Vandervoort |
| Title: | Chief Legal Officer and Secretary |
Document
Exhibit 99.1
Teladoc Health Appoints Susan Salka, Experienced Healthcare Executive, to Its Board of Directors
NEW YORK, March 30, 2026 -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Susan Salka to its board of directors, effective immediately. Ms. Salka is the former president and CEO of AMN Healthcare Services, a provider of healthcare workforce technology solutions and staffing services to healthcare facilities across the US. She joins following the retirements of Eric Evans and Thomas McKinley and the appointment of Michael Smith. She will serve on the board’s audit and compensation committees.
“Susan brings a powerful combination of healthcare leadership and governance experience to the Board,” said Kenneth H. Paulus, non‑executive Chairman of the Teladoc Health board. “We will benefit from her insights on care delivery transformation as the company drives health outcomes at scale and creates durable value.”
During her 33-year tenure at AMN Healthcare, Ms. Salka was one of the driving forces behind the company's strategic and operational success. AMN pioneered the evolution of workforce solutions and made 26 acquisitions to meet the changing needs of clients, transforming the company and growing revenue to over $5 billion.
Ms. Salka currently serves on the board of Parexel International and previously served on the boards of McKesson Corporation, Beckman Coulter and Playtex Products. She holds an MBA in Finance from San Diego State University and a BA in Accounting and Economics from Chadron State College.
“Integrated, outcomes focused care is central to creating lasting value in healthcare,” said Salka. “Teladoc Health is an innovative leader and I look forward to contributing strategic and operational perspectives on the company’s next phase of growth.”
About Teladoc Health
Teladoc Health (NYSE: TDOC) is the global leader in virtual care. The company is delivering and orchestrating care across patients, care providers, platforms, and partners — transforming virtual care into a catalyst for how better health happens. Through our relationships with health plans, employers, providers, health systems and consumers, we are enabling more access, driving better outcomes, extending provider capacity and lowering costs. Learn more at teladochealth.com.
Investors: Michael Minchak IR@teladochealth.com 617-444-9612
Media:
Lou Serio
PR@teladochealth.com
202-569-9715